Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis

Hyoeun Kim, Jaewon Oh, Sanghyup Lee, Jaehyung Ha, Minjae Yoon, Kyeong hyeon Chun, Chan Joo Lee, Sungha Park, Sang Hak Lee, Seok Min Kang

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients often do not receive sacubitril/valsartan because of concerns about hypotension. We examined the feasibility of initiating sacubitril/valsartan at a very low dose (VLD) in potentially intolerant patients with HFrEF and subsequent dose up-titration, treatment persistence and outcomes. We analyzed 206 patients with HFrEF grouped according to starting sacubitril/valsartan dose. The VLD group (n = 106) commenced 25 mg twice daily, and the standard-dose (SD) group (n = 100) started on ≥ 50 mg twice daily. Baseline systolic blood pressure was 103 ± 12 mmHg vs. 119 ± 14 mmHg in the SD group (P < 0.001). The maximal target dose achievement rate was higher in the SD group (27.0% vs 9.4%, p = 0.001) and the VLD group experienced more dose up-titrations and fewer down-titrations than the SD group. The VLD group had a decrease in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) similar to the SD group and a similar increase in left ventricular ejection fraction. There were no significant differences in symptomatic hypotension, worsening renal function, hyperkalemia, cardiovascular mortality, and rehospitalization due to HF between the two groups during follow-up period. In patients considered by the treating physician likely to be intolerant of sacubitril/valsartan, initiation with 25 mg twice daily was generally possible and patients remained in therapy, with similar decreases in NT-proBNP and increases in left ventricular ejection fraction to those observed in patients receiving SD sacubitril/valsartan.

Original languageEnglish
Article number16335
JournalScientific reports
Volume11
Issue number1
DOIs
Publication statusPublished - 2021 Dec

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

All Science Journal Classification (ASJC) codes

  • General

Fingerprint

Dive into the research topics of 'Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis'. Together they form a unique fingerprint.

Cite this